| 2025-03-28 | +0.24 % |
|
| 2025-03-26 | +0.95 % |
|
| 2025-03-25 | -4.06 % |
|
| 2025-03-20 | -1.45 % |
|
| 2025-03-19 | +1.11 % |
|
| 2025-03-18 | -1.98 % |
|
| 2025-03-17 | +1.73 % |
|
| 2025-03-14 | -2.02 % |
|
| 2025-03-12 | -3.99 % |
|
| 2025-03-11 | -3.58 % |
|
| 2025-03-07 | +1.3 % |
|
| 2025-03-06 | +1.64 % |
|
| 2025-02-27 | -0.59 % |
|
| 2025-02-26 | -2.28 % |
|
| 2025-02-24 | +1.84 % |
|
| 2025-02-21 | +0.62 % |
|
| 2025-02-19 | +0.83 % |
|
| 2025-02-18 | +0.95 % |
|
| 2025-02-14 | -0.1 % |
|
| 2025-02-13 | +1.57 % |
|
| 2025-02-12 | -0.24 % |
|
| 2025-02-11 | -3.61 % |
|
| 2025-02-10 | -2.77 % |
|
| 2025-02-07 | -1.67 % |
|
| 2025-02-06 | +0.75 % |
|
| 2025-02-05 | +2.82 % |
|
| 2025-02-04 | +4.53 % |
- Regeneron Pharmaceuticals (REGN) stock rose 4.53% following the company's strong fourth-quarter earnings report, which included a 2% year-over-year increase in adjusted EPS that exceeded expectations, sales growth of 10% beating consensus estimates, the announcement of a new quarterly cash dividend, and an authorization of an additional $3 billion for share repurchases.
- Regeneron Pharmaceuticals (REGN) stock rose 4.53% following the company's positive financial results for Q4 and full year 2024, alongside the announcement of a new quarterly dividend program and increased share repurchase capacity, highlighting robust revenue growth and successful pipeline advancement in their R&D initiatives.
- Regeneron Pharmaceuticals (REGN) stock rose 4.53% last night amid ongoing scrutiny over potential legal issues related to alleged misleading statements concerning their Eylea drug pricing and sales practices, which have led to DOJ investigations. The stock increase could be attributed to investor sentiment responding positively to the legal developments or market anticipation for company performance improvements following recent challenges.
- Regeneron Pharmaceuticals' stock rose following strong fourth-quarter sales and profit results that exceeded analysts' expectations, driven by heightened demand for its eczema treatment Dupixent, a dividend announcement, and an expansive share buyback program. The stock's increase can be attributed to better-than-expected financial performance, including additional revenue from Eylea and Libtayo, and strategic initiatives like the dividend and buyback that enhance shareholder value.
- Regeneron Pharmaceuticals (REGN) stock rose by 4.53% after the company exceeded fourth-quarter sales and profit expectations due to strong demand for its eczema treatment, Dupixent, while also introducing a dividend and stock buyback program.
- Regeneron Pharmaceuticals (REGN) stock rose 4.53% following the company’s announcement of stronger-than-expected fourth-quarter earnings of $12.07 per share and $3.79 billion in sales, surpassing analyst expectations.
|
| 2025-02-03 | -0.91 % |
|
| 2025-01-31 | -1.48 % |
|
| 2025-01-29 | +0.14 % |
|
| 2025-01-28 | +0.24 % |
|
| 2025-01-27 | +1.32 % |
|
| 2025-01-24 | -2.71 % |
|
| 2025-01-22 | -1.13 % |
|
| 2025-01-21 | +0.91 % |
|
| 2025-01-17 | -1.68 % |
|
| 2025-01-16 | -1.45 % |
|
| 2025-01-15 | +1.82 % |
|
| 2025-01-14 | -3.63 % |
|
| 2025-01-13 | +2.87 % |
|
| 2025-01-10 | -5 % |
|
| 2025-01-08 | +0.45 % |
|
| 2025-01-07 | +1.96 % |
|
| 2024-12-19 | -0.89 % |
|
| 2024-12-06 | +1.32 % |
|
| 2024-12-04 | +0.63 % |
|
| 2024-12-03 | -1.68 % |
|
| 2024-11-27 | +0.24 % |
|
| 2024-11-21 | +0.15 % |
|
| 2024-11-19 | -2.28 % |
|
| 2024-11-18 | +0.69 % |
|
| 2024-11-15 | -3.28 % |
|
| 2024-11-14 | -2.71 % |
|
| 2024-11-11 | -0.33 % |
|
| 2024-11-08 | +0.48 % |
|
| 2024-11-06 | -1.54 % |
|
| 2024-11-05 | +0.07 % |
|
| 2024-10-31 | -9.17 % |
|
| 2024-10-30 | -0.49 % |
|
| 2024-10-29 | -0.14 % |
|
| 2024-10-28 | -0.47 % |
|
| 2024-10-25 | +0.44 % |
|
| 2024-10-24 | -1.33 % |
- Regeneron Pharmaceuticals (REGN) stock fell by -1.33%, possibly due to market volatility or investor reactions to new disclosures, such as Lecap Asset Management Ltd. acquiring a small position in the company.
- Regeneron Pharmaceuticals (REGN) stock declined by -1.33% following Wells Fargo's downgrade of its price target from $1,200 to $1,050, despite maintaining an "overweight" rating for the company.
- Regeneron Pharmaceuticals (REGN) stock fell by 1.33% after OLD National Bancorp IN reduced its stake by 21.6%, indicating potential shifts in institutional investor sentiment.
- Regeneron Pharmaceuticals (REGN) stock fell by 1.33% after JPMorgan Chase & Co. reduced its price target from $1,200.00 to $1,150.00 while maintaining an "overweight" rating, indicating a potential decrease in expected value.
- Regeneron Pharmaceuticals (REGN) stock declined by 1.33% amid recent analyst updates on ratings and price targets, combined with insider stock sales potentially signaling a lack of confidence or volatility in its near-term outlook.
- Regeneron Pharmaceuticals (REGN) stock decreased by 1.33% after institutional investors adjusted their positions, with some hedge funds increasing their stakes while others hedged by selling shares, and mixed analyst ratings influencing market sentiment.
The drop in stock price is attributed to recent changes in institutional investments and varying analyst ratings that may have caused uncertainty among investors.
- Regeneron Pharmaceuticals (REGN) stock fell by 1.33% despite receiving an upgrade from analysts and several positive price target adjustments from various brokerages, indicating possible market reactions to broader economic factors or investor sentiment.
The decline in Regeneron's stock could be attributed to general market trends or investor profit-taking after steady increases, rather than specific negative news about the company.
|
| 2024-10-23 | -2.18 % |
|
| 2024-10-22 | -0.64 % |
|
| 2024-10-21 | -2.24 % |
|
| 2024-10-18 | -0.76 % |
|
| 2024-10-15 | +0.22 % |
|
| 2024-10-14 | -0.14 % |
|
| 2024-10-10 | -1.3 % |
|
| 2024-10-09 | +0.69 % |
|
| 2024-10-07 | -1.66 % |
|
| 2024-10-02 | -0.63 % |
|
